Seattle Pain Relief PLLC
Seattle Pain Relief PLLC was paid $1.04M by Medicaid between Jan 2018 and Dec 2024, across 29 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 36% of everything it billed.
33Billing provider infoSEATTLE PAIN RELIEF PLLC
FEDERAL WAY, WA 98003
FEDERAL WAY, WA 98003
33aNPI1710240841assigned 06/22/2012
33bProvider typeChiropractor
28Total paid$1.04M
24GClaims43,062
24DCodes billed29
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Chiropractor providers in Washington
Rank by total paid#2 of 48
Median peer was paid$7K
This provider vs. median147×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BIRDSALL, DAVID controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,298 | $21K | |
| 2019 | 8,489 | $210K | |
| 2020 | 9,722 | $329K | |
| 2021 | 6,883 | $297K | |
| 2022 | 5,324 | $174K | |
| 2023 | 4,666 | $7K | |
| 2024incomplete | 3,680 | $5K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 36% | 6,110 | 5,517 | $371K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 27% | 12,721 | 9,366 | $277K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 19% | 8,636 | 7,750 | $195K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.0% | 4,039 | 3,364 | $52K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 3.3% | 1,521 | 1,406 | $34K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 2.9% | 338 | 332 | $30K |
| L0650 | Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | 1.7% | 20 | 19 | $18K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 1.3% | 474 | 380 | $14K |
| 99205 | Prolong outpt/office vis | <1% | 160 | 156 | $9K |
| 20553 | <1% | 549 | 380 | $7K | |
| 76942 | <1% | 490 | 315 | $6K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 79 | 73 | $6K |
17 more codes
| 77002 | <1% | 334 | $5K | |
| 99152 | <1% | 263 | $4K | |
| 96132 | <1% | 1,630 | $2K | |
| 96130 | <1% | 1,628 | $2K | |
| 10021 | <1% | 159 | $1K | |
| 10022 | <1% | 204 | $1K | |
| L1832 | Knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 20 | $1K |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 1,619 | $1K |
| 99443 | <1% | 45 | $965.88 | |
| 20552 | <1% | 44 | $938.97 | |
| 20610 | <1% | 98 | $821.60 | |
| 27096 | <1% | 13 | $770.88 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 60 | $406.50 |
| 96138 | <1% | 1,630 | $329.84 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 44 | $152.16 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 16 | $28.24 |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 118 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBIRDSALL, DAVID (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Cep America - California | Gilroy, CA | $59.58M |
| Cep America - California | Moreno Valley, CA | $32.76M |
| Cep America - California | Modesto, CA | $31.92M |
| Cep America - California | Modesto, CA | $25.97M |
| Cep America - California | Salinas, CA | $22.20M |
| Cep America - California | San Bernardino, CA | $19.62M |
| Cep America - California | Colton, CA | $16.76M |
| Cep America - California | Marysville, CA | $14.57M |
| Cep America - California | French Camp, CA | $14.51M |
| Cep America - California | Chula Vista, CA | $14.39M |
| Cep America - California | Pomona, CA | $13.68M |
| Cep America - California | Montebello, CA | $13.62M |
| Cep America - California | Redding, CA | $13.32M |
| Cep America - California | Antioch, CA | $12.62M |
| Cep America - California | Mission Hills, CA | $12.48M |
| Cep America - California | San Bernardino, CA | $12.30M |
| Cep America LLC | Baltimore, MD | $12.03M |
| Cep America - California | Santa Cruz, CA | $12.00M |
| Cep America - California | San Mateo, CA | $11.52M |
| Cep America - California | Riverside, CA | $10.50M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.